Lipocine Inc.
LPCNNASDAQHealthcare● Active
$2.04
$-0.01(-0.49%)
Market Cap$11839154
P/E Ratio—
52W High$12.37
52W Low$1.81
Lipocine Inc. (LPCN) · Income Statement
Annual, quarterly, or TTM views · SEC 10-K & 10-Q via FMP · adjust period and M/B/T below.
FMP · LPCN · as of 2026-06-09
Financial statements
Revenue · Gross Profit · Net Income
| Breakdown | 2025-12 | 2024-12 | 2023-12 | 2022-12 | 2021-12 |
|---|---|---|---|---|---|
| Revenue | |||||
| Revenue | $1.98M | $11.20M | ($2.85M) | $0.50M | $16.14M |
| Cost of Revenue | $8.58M | $0.00M | $10.18M | $8.56M | $7.67M |
| Gross Profit | ($6.61M) | $11.20M | ($13.03M) | ($8.06M) | $8.48M |
| Gross Margin %(computed) | -334.26% | 100.00% | 456.92% | — | 52.51% |
| Operating Expenses | |||||
| R&D Expenses | $0.00M | $7.35M | $0.00M | $0.00M | $0.00M |
| G&A Expenses | $3.76M | $5.00M | $4.90M | $4.06M | $5.33M |
| Total Operating Expenses | $3.76M | $12.35M | $4.90M | $4.06M | $5.33M |
| Operating Income | ($10.37M) | ($1.16M) | ($17.93M) | ($12.12M) | $3.15M |
| Operating Margin %(computed) | -524.69% | -10.31% | 628.98% | — | 19.49% |
| Interest Income | $0.74M | $1.15M | $1.37M | $0.57M | $0.07M |
| Interest Expense | $0.00M | $0.00M | $0.00M | $0.03M | $0.20M |
| Income Before Tax | ($9.63M) | $0.01M | ($16.35M) | ($10.76M) | ($0.63M) |
| Income Tax Expense | $0.00M | $0.00M | $0.00M | $0.00M | $0.00M |
| Net Income | ($9.63M) | $0.01M | ($16.35M) | ($10.76M) | ($0.63M) |
| Net Margin %(computed) | -487.06% | 0.07% | 573.59% | — | -3.93% |
| Per Share & EBITDA | |||||
| EPS (Basic) | $-1.77 | $0.00 | $-3.14 | $-2.15 | $-0.19 |
| Wtd Avg Shares | 5.45M | 5.34M | 5.27M | 4.99M | 3.30M |
| EBITDA | ($10.31M) | ($1.11M) | ($17.90M) | ($10.72M) | ($0.43M) |
| EBITDA Margin %(computed) | -521.61% | -9.95% | 627.97% | — | -2.67% |
Data source: Financial Modeling Prep · Last updated: 2026-06-09 · USD · M
Explore more Lipocine Inc. data
About Lipocine Inc. (LPCN) Income Statement
Lipocine Inc. (LPCN) income statement data is sourced from SEC Form 10-K and 10-Q filings. For fiscal year 2025, LPCN reported revenue of $0.00B, gross profit of ($0.01B) (gross margin -334.26%), and net income of ($0.01B) — a net profit margin of -487.06%.
Frequently asked questions
LPCN · 4 questionsLipocine Inc. (LPCN) reported revenue of $0.00B for 2025, down 82.3% year-over-year.
LPCN revenueLPCN salesannual revenue YoYincome statement
· Source: FMP /stable/income-statement · SEC EDGAR Form 10-K & 10-Q · As of 2026-06-09